Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 8Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Burkitt Lymphoma 6Small Cell Lung Carcinoma 5Lymphoma, T-Cell 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × MLN 8237 × Clear all
NCT02186509 2025-04-30

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Thomas Jefferson University

Phase 1 Completed
17 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡